MIRA
INFORM REPORT
|
Report Date : |
31.07.2008 |
IDENTIFICATION
DETAILS
|
Name : |
MATRIX PHARMACEUTICAL |
|
|
|
|
Registered Office : |
PMD 31, A – 7, Road No. 8, Ghatkopar Mankhurd Link Road, Govandi (East),
Mumbai – 400 043, Maharashtra |
|
|
|
|
Country : |
India |
|
|
|
|
Financials (as on) : |
31.03.2008 |
|
|
|
|
Year of Establishment : |
2007 |
|
|
|
|
PAN No: |
AQLPP3925G |
|
|
|
|
Legal Form : |
Sole Proprietory Concern |
|
|
|
|
Line of Business : |
Manufacturer of Pharmaceutical Products. |
RATING &
COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit consideration.
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
Maximum Credit Limit : |
USD 25000 |
|
|
|
|
Status : |
New Concern |
|
|
|
|
Payment Behaviour : |
Slow |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is a new concern meeting its smaller commitments slightly over
times as reported. Trade relations are fair. Business is active. The concern can be considered good for small to mediocre business
dealings. |
INFORMATION PARTED
BY
|
Name : |
Mr. Ram Patel |
|
Designation : |
Proprietor |
|
Date : |
23.07.2008 |
LOCATIONS
|
Registered Office : |
PMD 31, A – 7, Road No. 8, Ghatkopar Mankhurd Link Road, Govandi
(East), Mumbai – 400 043, Maharashtra, India |
|
Tel. No.: |
91-22-25566192 |
|
Mobile No.: |
91-9221396781 |
|
Website : |
|
|
|
|
|
Factory : |
508, Sampati Sonau, Himachal Pradesh, India |
|
Location : |
Rented |
|
|
|
|
Manufacturing Plant : |
G I D C, Odhav, Opp. Ambicanagar, Ahmedabad – 382 415, Gujarat, India |
|
Tel. No.: |
91-79-22871879 |
|
Fax No.: |
91-79-22972210 |
|
E-Mail : |
PROPRIETOR
|
Name : |
Mr. Ram Kishore Patel |
|
Designation : |
Proprietor |
|
Date of Birth/Age : |
26 Years |
|
Qualification : |
B. Pharma |
BUSINESS DETAILS
|
Line of Business : |
Manufacturer of Pharmaceutical Products. |
|
|
|
|
Products : |
|
|
|
|
|
Exports : |
|
|
Countries : |
v USA v UK |
|
|
|
|
Imports : |
|
|
Products : |
v Raw Material |
|
Countries : |
v China |
|
|
|
|
Terms : |
|
|
Selling : |
L/C, Cash and Credit ( 7 – 15 Days) |
|
|
|
|
Purchasing : |
L/C, Cash and Credit ( 7 – 15 Days) |
GENERAL
INFORMATION
|
Customers : |
v Wholesalers v Retailers v Distributor v Manufacturer v Trader |
|
|
|
|
No. of Employees : |
10 |
|
|
|
|
Bankers : |
v Bank of India Ghatkopar v Axis Bank Ghatkopar |
|
|
|
|
Auditors : |
|
|
Name : |
Mr. Mahendra Jain Chartered Accountants |
|
Address : |
Panvel |
|
|
|
|
Sister Concerns : |
v P M Liernes Address: Himachal
Pradesh Line of Business
:
Manufacturer of Pharmaceutical Products. v WHO – GMP Address : Himachal Pradesh Line of Business
:
Manufacturer of Pharmaceutical Products. |
CAPITAL STRUCTURE
|
Capital Investment : |
|
|
Owned : |
Rs. 5.000 millions |
|
Borrowed : |
-- |
|
Total : |
Rs. 5.000 millions |
FINANCIAL DATA
[all figures are in Rupees Millions]
|
Particulars |
|
|
31.03.2008 |
|
Sales Turnover |
|
|
2.000 |
Expected Sales (2008-09): Rs. 20.000 millions
LOCAL AGENCY
FURTHER INFORMATION
Trade References
v
Cipla Limited – India
v
Paytico Limited – India
v
Vockharad Limited - India
Trust Seal Acceptance Chart
|
Parameters |
Details |
|
Existence Verification |
|
|
Name |
Matrix Pharmaceutical |
|
|
|
|
Statutory Approvals |
|
|
Legal Status of Firm |
Proprietor |
|
Income Tax Registration |
AQLPP3925G |
|
Name of Bank |
Axis Bank Bank of India |
|
Account Since |
1 Year |
|
|
|
|
Credibility Factors |
|
|
India mart Client Since |
2 Years |
As Per Website Details
Catering to the market requirements of superior grade of pharmaceutical products, they established the concern Subject as traders and contract manufacturers of fine quality allopathic and generic drugs that are approved by FDA -WHO-GMP / ISO / schedule-M certificates. The range offered by us include anti allergic and anti diabetic, life saving drugs, harmonal , anti aids, anti fungal, sex stimulants, analgesic, anti hypertensive medicine, anti biotic, cardiovascular, anti depressants, contraceptives, women sex enhancement capsules and many more. Under the able guidance of the mentor Mr. Mahipal Singh, who is the Proprietor of the concern, they have developed the expertise in contract manufacturing of various pharmaceutical formulation.
Established in the year 1999,
the consistency in sourcing quality drugs from reputed manufacturers has
enabled us to achieve a notable presence in the industry.
The in house testing facilities comprising of well- equipped laboratories and
latest apparatus assist us in inspecting the quality of the sourced products
and assuring the clients of procuring from us the best range of drugs
available.
Also undertake contract manufacturing of Tablets and
Capsules, Soft geletin cap ,Injections, Liquids, Eye/Ear Drops and Ointments
Commitment
They are committed towards serving the clients in the best, efficient and complete manner
v They are specialized in drop shipping.
v They give worldwide delivery
v They offer guaranteed delivery
v Quick Shipment
v Packaging as per customer's requirement
v A wide range of products
v Best quality products at lowest possible prices (Very competitive pricing)
v Right quality generics
v Customer support and Quick response time
v Greater levels of services at the lowest prices
Clients
Asia, Africa and Oceania:
Algeria,
Australia, Bahrain, China, Djibouti, Egypt, Ethiopia, Indonesia, Iran, Iraq,
Japan, Jordan, Kenya, Korea, Malaysia, Mauritius, Mongolia, New Zealand,
Nigeria, Oman, Philippines, Qatar, Saudi Arabia, Seychelles, Singapore, Sri
Lanka, Sudan, Taiwan, Tanzania, Thailand, UAE, Uganda, Vietnam, Yemen, Zambia,
Zimbabwe.
Europe:
Belarus, Bulgaria, Bosnia and Herzegovina, Croatia, Cyprus, Czech Republic,
Denmark, Estonia, Finland, France, Greece, Germany, Hungary, Italy, Kazakhstan,
Kyrghyzstan, Latvia, Netherlands, Poland, Portugal, Romania, Russian
Federation, Slovakia, Slovenia, Spain, Sweden, Turkey, Ukraine, Uzbekistan,
Serbia and Montenigro.
North and South America:
Argentina,
Bahamas, Brazil, Canada, Columbia, Cuba, Dominican Repuplic, Mexico, Peru, Suriname,
Uruguay, USA.
Bilateral
Afghanistan, Armenia, Austria, Belgium, Botswana, Brunei, Dubai, Ghana, Guyana,
Hong Kong, Iceland, Israel, Lesotho, Libya, Luxembourg, Namibia, Nepal, Norway,
Mozambique, Pakistan, Senegal, South Africa, Switzerland, Syria, Zanzibar
(Sole and Complete
Contract Manufactured)
MPI matrix pharmaceuticals (India) manufactured by a
widespread range of branded pharmaceutical formulation and generics products in
almost any form. They welcome importers, distributors, wholesaler and agents.
MPI provides basket of services like Dossiers, Leaflets , In-House Designing of
Labels and Cartons .MPI has well documented regulatory department as well as
prompt and reliable assistance for all the customers.
Contract manufacturing of Tablets , capsule , Soft gelatin cap , Injection ,
Eye /Ear /Nasal drops , Liquid , Lotion ,
Inhalers , Cream , Ointment ,
Neutraceuticals , Soap , Shampoo.
Herbal Product and Veterinary
Product MPI offers flexible terms of trade and gives each customer a personal
attention. All products can be supplied in the various permitted/suitable
dosages and in required pack sizes in the form of small volume liquid
parenterals, dry powder injectables, tablets (uncoated, sugar coated, enteric
coated, film coated, chewable, lozenges, Delayed Release, Sustained release and
dispersible forms), capsules, dry syrups, liquid orals, sterile eye drops and
ear drops and topical lotions for external applications.
The aim is to provide Affordable, Latest and High Quality Finished Formulations
with Latest and Hygienic Packaging, which will benefit the end customer.
Kindly contact us for the requirements to enable us to give you the best rates.
They offer the products on third party basis and under neutral label for export
Products.
They manufacture the own brands as
well as under neutral labels as required by the buyers in any of languages.
Catering as per customers' requirements is the specialization. The quality formulations
and bulk drugs are exported worldwide.
Drugs Quality
v
World Health Organization
(WHO)
v
Food and Drug Administration
(FDA), USA
v
Medicines Control Agency
(MCA), UK
v
Therapeutic Goods
Administration (TGA), Australia
v
Medicines Control Council (MCC),
South Africa
v
National Institute of
Pharmacy (NIP), Hungary
v
Food and Drug Administration
(FDA), India
v
Pharmaceutical Inspection
Convention (PIC), Germany
v
State Institute for the
Control of Drugs, Slovak Republic
Contract Manufactured
Plant
The manufacturing facilities at various locations in India. At Himachal Pradesh, Utrakhand (U.K), Rajasthan, Gujarat, Maharastra ,Tamilnadu This helps us meet the logistics demand of the customers.
The modern plants are equipped with the latest machines in Blow Moulding,
Injection Moulding, Screen Printing, Thermal Transfer, UV Offset Printing, Foil
Stamping, Shrink Sleeving and Labelling.
A lot of emphasis is placed on training and good manufacturing practices at all
the plants. They have very strong systems such as Kaizen, Kanban and Baddi,
Tinsukia, Dadra and Daman, Umargaon, Silvasa, Pune, Pondicherry, Sriperumbudur.
Manufacturing
Facilities (Plant)
India
v
Himachal Pradesh (HP)
v
Uttarakhand (UK)
v
Punjab (PB)
v
Rajasthan (RJ)
v
Gujarat (GJ)
v
Maharashtra (MH)
v
Tamalinadu
Packing and Label
They request the buyers to provide
us specific requirements about labeling at the time of placing the order or
inquiry. Once they have the sufficient information, they will give the
confirmation or clarifications to avoid clearance problems.
Normally the labels have the details like product name with the pharmacopoeia
mentioned, manufacturing date, expiry date, license number, net wt, gross wt.
or quantity in case of formulations
Packing Alu-Alu blister, Tropical blisters, Liquid filled blister, Child
resistant blister, Carded blister, Transparent blister.
CMT REPORT
(Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources including
but not limited to: The Courts, India Prisons Service, Interpol, etc.
1] INFORMATION ON
DESIGNATED PARTY
No exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist organization
or whom notice had been received that all financial transactions involving
their assets have been blocked or convicted, found guilty or against whom a
judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper
payments to government officials for engaging in prohibited transactions or
with designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction registered
against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority
for any financial crime or under any formal investigation by a competent
government authority for any violation of anti-corruption laws or international
anti-money laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling shareholders,
director, officer or employee of the company is a government official or a
family member or close business associate of a Government official.
9] Compensation Package :
The market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE
GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on Corporate
Governance to identify management and governance. These factors often have been
predictive and in some cases have created vulnerabilities to credit
deterioration.
The Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE
RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs. 42.47 |
|
UK Pound |
1 |
Rs. 84.00 |
|
Euro |
1 |
Rs. 66.14 |
SCORE & RATING
EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
3 |
|
PAID-UP CAPITAL |
1~10 |
3 |
|
OPERATING SCALE |
1~10 |
3 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
4 |
|
--PROFITABILIRY |
1~10 |
2 |
|
--LIQUIDITY |
1~10 |
3 |
|
--LEVERAGE |
1~10 |
3 |
|
--RESERVES |
1~10 |
3 |
|
--CREDIT LINES |
1~10 |
3 |
|
--MARGINS |
-5~5 |
-- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
NO |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
YES |
|
--AFFILIATION |
YES/NO |
YES |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
27 |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit consideration.
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, they have no basis upon which to
recommend credit dealings |
No Rating |
|